IL17A and diabetes mellitus: As shown in Figure 4A, weekly intraperitoneal injections of 100 μL of saline containing 10 μg/mL, 25 μg/mL, or 50 μg/mL of anti-IL17A was administered to non-diabetic (wild-type heterozygous Leprdb mice) and Leprdb Type II diabetic mice; 1 week after diabetes was confirmed with an FBG score greater than 275 mg/dL (Figure 4A).